Amarin Corp Plc (AMRN)

[ralphey]

It seems like the TEVA lawyer makes AMRNS case ?

William Jay of Goodwin Procter, arguing for Teva, said his client had precisely followed the federal Hatch-Waxman Act in carving out uses that GSK had identified as patented in submissions to the Food and Drug Administration.
"The carve-out provision of Hatch-Waxman was designed for just this situation, where the drug is not patented and the vast majority of uses, more than 80%, are not patented," he said.

REDUCE IT use is patented !